Cohort Study | Prevalence, outcomes and costs of a contemporary, multinational population with heart failure

Summary: The CardioRenal and Metabolic disease (CaReMe) HF study estimated the prevalence, clinical outcomes, and costs of heart failure (HF) across 11 countries using digital healthcare systems. The study found that the prevalence of HF was 1-2%, with the most frequent comorbidities being ischemic heart disease and chronic kidney disease (CKD) stages III– V.

Furthermore, the study revealed that hospital care costs were highest for cardiorenal diseases, even higher than those stemming from atherosclerotic cardiovascular diseases. This emphasizes the urgent need for improved risk management and healthcare planning for patients with HF, particularly those with cardiorenal complications.*

Article: Prevalence, outcomes and costs of a contemporary, multinational population with heart failure – Heart

News Release: Up to 2% of adults in Europe, North America, Israel likely have heart failure – BMJ Newsroom

Commentary: Multinational Study Details Contemporary Prevalence, Treatment Strategies of Heart Failure – HCP Live

*Note: This summary was created through the collaboration of a medical editor and ChatGPT.